These results demonstrate a highly significant improvement in the associations with treatment response and outcomes when ctDNA score changes are included.
← all excerpts
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.
1
—
—